Back to search results

Teleconsultation for CTD-ILD Care in Rural Areas (TRUST Initiative)

This observational study, called the TRUST Initiative, is looking at how well teleconsultations (virtual doctor visits) work for people with connective tissue disease-associated interstitial lung disease (CTD-ILD). This is a lung condition that can happen with autoimmune diseases like rheumatoid arthritis. The study aims to help people in rural areas get specialized care, as these clinics are often in cities. We want to see if patients are satisfied with this teleconsultation approach. You might be able to join if you are an adult aged 18 or older with a confirmed diagnosis of CTD-ILD. The study plans to enroll 10 participants, and the current status is unclear.

Study design
This is an observational study, meaning researchers will watch and collect information without giving any specific interventions. It plans to include 10 participants.
What's involved
Not specified in the trial record.
Compensation
Not stated in the trial record.
Follow-up
Patient satisfaction will be measured at 12 months.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT07217093

Teleconsultation Approach to CTD-ILD Care Delivery in Rural UnderServed CommuniTies (TRUST Initiative)

Not Yet Recruiting
Not specifiedAges 18+Observational
St. Lawrence Health System
~10 participants
Updated 2025-10-15 on ClinicalTrials.gov

At a glance

Recruiting sites
0 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Patient Satisfaction
Measured over 12 months

Conditions

Interstitial Lung Disease Due to Systemic Disease (Disorder)
Interstitial Lung Disease in Patients With Rheumatoid Arthritis
Interstitial Lung Disease Due to Systemic Disease

Explore related trials

Interstitial lung disease due to connective tissue disease

NCT07217093

Where you'd take part

This study runs at 1 site. They're the same protocol — you choose where, and that choice sets who your contact draft is addressed to.

  • St. Lawrence Health

    Potsdam, New Yorkstudy coordinator listed

Sites open and close at different times, so the status above is per site — it can differ from the study's overall status.

Who to contact

Autumn Thompson
[email protected]
315-261-5611
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Want this trial checked against your situation?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Confirmed diagnosis of connective tissue disease-associated interstitial lung disease (CTD-ILD) by a physician based on clinical, radiographic, and/or pathological criteria. CTDs may include scleroderma, systemic lupus erythematosus, rheumatoid arthritis, mixed connective tissue disease, Sjogren's disease (primary or secondary), inflammatory myopathy including but not limited to dermatomyositis and polymyositis, or any overlap syndrome including one or more of these diseases.
Diagnosis of CTD-ILD established at least one year prior to enrollment 3. Residence:
Full time resident (at least six months per year) of one of the seven counties of the North Country region of New York (St. Lawrence, Franklin, Jefferson, Lewis, Hamilton, Clinton, Essex) 4. Active Care Relationship:
Documented diagnosis of CTD-ILD via any of the following:
Determination by PI
Or an active SLH medical record (≥1 clinical encounter, test, or treatment in past 24 months) 5. Pulmonary Function Testing and safety labs:
Ability and willingness to perform pulmonary function and safety lab tests at local facilities as required by the study protocol.
Most recent PFT within 24 months prior to baseline 6. Consent:
Provide written informed consent to participate in the study, including consent for data collection and telehealth consultations.

Exclusion

Individuals with severe cognitive dysfunction or mental health conditions that, in the judgment of the PI, would interfere with the ability to provide informed consent or participate in teleconsultation sessions.
Participants with a life expectancy of less than six months due to any cause, as determined by the PI.
Individuals with other severe pulmonary conditions determined by PI with input from Sub-Is (e.g., chronic obstructive pulmonary disease \[COPD\], pulmonary fibrosis unrelated to CTD-ILD, or active lung cancer) that may confound the assessment of CTD-ILD progression.
Participants who are unable to perform or complete the required pulmonary function tests because of physical limitations (e.g., significant respiratory distress or severe disability) or non-compliance.
Individuals currently participating in another interventional clinical trial for CTD-ILD or other chronic lung diseases that could interfere with the study outcomes.
Participants who, in the judgment of the PI, are unlikely to comply with the study protocol or follow-up requirements (e.g., inability to attend teleconsultations, failure to complete pulmonary function tests, or non-adherence to study treatment regimen).
Participants who are currently receiving treatment by an ILD specialist at an ILD center at an academic medical center are not eligible to participate in this study.
Pregnant or breastfeeding women.

What this trial measures

  • Patient Satisfaction12 months

    a. Scores from a patient satisfaction survey to assess the perceived quality of teleconsultations-based care including assessments of quality and access to care, cost, and timesaving related to the teleconsultation model. Conducted at the baseline, 6 month, and 12 month visits.